The Motley Fool: Johnson & Johnson Continues To Play To Its Strengths

I continue to be impressed with the strength Johnson & Johnson has been showing of late. The only fly in the ointment is that it's not a particularly well-balanced strength, as the company's drug business is really driving the improvements. As ointment-flies go, though, that's really not so bad and the company continues to see respectable performance in key categories like cardiology, orthopedics, and surgery. Johnson & Johnson isn't particularly undervalued today, but investors should nevertheless be able to expect high single-digit to low double-digit returns from this point, which is pretty compelling for investors looking for a quality long-term holding.

Read more here:
http://www.fool.com/investing/general/2013/10/15/johnson-johnson-continues-to-play-to-its-strengths.aspx